Mutations in FLT3 lead to the constitutive activation of the FLT3 receptor tyrosine kinase which is found in about one-quarter of AMLs, therefore being considered the most common genetic alteration in AML causing aggressive hematologic malignancy associated with poor prognosis which frequently relapses [72,73,74,75,76,77,78,79]. The gene discussed is NTRK1; the disease is acute myeloid leukemia.